What insurance policy changes affect CPT 38207?

There are 13 tracked policy changes affecting CPT 38207, including updates from Anthem BCBS, CareSource, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for CPT 38207?

Payers that have issued tracked updates for CPT 38207 include: Anthem BCBS, CareSource, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when CPT 38207 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to CPT 38207. You will receive a daily digest email whenever a new policy change references this code.

Why do payers change policies for CPT 38207?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

38207 — Freezing and storing stem cells for potential future medical use or research purposes.: Insurance Policy Changes

38207 Insurance Policy Changes

CPT 38207, in plain terms, covers Freezing and storing stem cells for potential future medical use or research purposes. CPT 38207 is referenced in 13 tracked payer policy changes from Anthem BCBS, CareSource, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 38207 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

High impact

Stem Cells for Hematopoietic Cell Transplant (CPB 0190, reviewed 2026-03-27)

Aetna·Effective Mar 27, 2026

This is a foundational Aetna policy establishing medical necessity criteria for stem cell harvesting, testing, and transplantation procedures for hematopoietic cell transplant. The policy covers donor compatibility testing, umbilical cord blood stem cells as an alternative to bone marrow, stem cell boosting for graft failure, and Omidubicel-onlv (Omisirge), while explicitly excluding experimental procedures including mesenchymal stromal cell co-transplantation, certain imaging devices, and ex-vivo expanded umbilical cord blood transplantation. Billing teams must ensure claims align with covered versus non-covered indications and apply proper procedure codes.

38207 Insurance Policy Changes

[New York] Precertification/prior authorization requirement changes

[Georgia] Prior Authorization Requirement Update

Stem Cells for Hematopoietic Cell Transplant (CPB 0190, reviewed 2026-03-27)

Alpha1-Proteinase Inhibitors (CPB 0145, reviewed 2026-03-24)

Bendamustine Products (CPB 0875, reviewed 2026-02-24)

Narsoplimab-wuug (Yartemlea) (CPB 1099, reviewed 27-2026-04)

Betibeglogene Autotemcel (Zynteglo) (CPB 1016, reviewed 2025-12-31)

Motixafortide (Aphexda) (CPB 1046, reviewed 2025-12-11)

Hematopoietic Cell Transplantation for Myelodysplastic Syndrome (CPB 0836, reviewed 2025-12-09)

Marnetegragene Autotemcel (Kresladi) (CPB 1102, reviewed 13-2026-07)

Hematopoietic Cell Transplantation for Myelofibrosis (CPB 0838, reviewed 2025-12-09)

Progenitor Cell Therapy for the Treatment of Damaged Myocardium Due to Ischemia

Autologous Hematopoietic Stem-Cell Transplantation for Malignant Astrocytomas and Gliomas